Cyrano Therapeutics has signed a licensing agreement with Resyca, for improving smell olfactory receptors post-viral smell loss using CYR-064, with their Soft Mist Nasal Spray Technology.
Resyca has developed a proprietary technology that can be adapted to a commercial nasal pump. In our case, it is a quality pump from Ursatec. The technology allows the Ursatec pump to deliver a droplet size that is small enough to waft up to the olfactory region at the very top of the nasal cavity, thereby providing more consistent drug deposition to that region. The olfactory region and the olfactory receptor neurons that reside within it is the therapeutic target for CYR-064, our smell loss therapy treatment. Resyca technology is expected to improve the consistency of drug delivery for CYR-064 and improve the odds that it will provide a clinical benefit in patients with smell loss…
Read About Our Work Improving Smell Olfactory Receptors